OBJECTIVE: The purpose of this study was to quantify the rate of exposures to antidepressants during pregnancy in a large cohort of women. STUDY DESIGN: This was a retrospective cohort study of 105,335 pregnancies among women enrolled in Tennessee Medicaid from 1999-2003. Pregnancies were classified according to antidepressant exposures during pregnancy using previously validated computerized pharmacy records linked with birth certificates. RESULTS: During the study period, 8.7% of women giving birth had exposure to any antidepressant; 6.2% had exposure to a selective serotonin reuptake inhibitor. Maternal age > 25 years (P < .0001), white race (P < .0001), and education > 12 years (P = .008) were significant predictors of antidepressant exposure. The proportion of pregnancies with antidepressant use increased from 5.7% of pregnancies in 1999 to 13.4% of pregnancies in 2003 (p < .0001). The increase was mostly accounted for by increases in selective serotonin reuptake inhibitor exposures. CONCLUSION: There is an urgent need for further studies that better quantify the fetal consequences of exposure to antidepressants.
OBJECTIVE: The purpose of this study was to quantify the rate of exposures to antidepressants during pregnancy in a large cohort of women. STUDY DESIGN: This was a retrospective cohort study of 105,335 pregnancies among women enrolled in Tennessee Medicaid from 1999-2003. Pregnancies were classified according to antidepressant exposures during pregnancy using previously validated computerized pharmacy records linked with birth certificates. RESULTS: During the study period, 8.7% of women giving birth had exposure to any antidepressant; 6.2% had exposure to a selective serotonin reuptake inhibitor. Maternal age > 25 years (P < .0001), white race (P < .0001), and education > 12 years (P = .008) were significant predictors of antidepressant exposure. The proportion of pregnancies with antidepressant use increased from 5.7% of pregnancies in 1999 to 13.4% of pregnancies in 2003 (p < .0001). The increase was mostly accounted for by increases in selective serotonin reuptake inhibitor exposures. CONCLUSION: There is an urgent need for further studies that better quantify the fetal consequences of exposure to antidepressants.
Authors: Nancy K Grote; Jeffrey A Bridge; Amelia R Gavin; Jennifer L Melville; Satish Iyengar; Wayne J Katon Journal: Arch Gen Psychiatry Date: 2010-10
Authors: Richard A Epstein; William V Bobo; Peter R Martin; James A Morrow; Wei Wang; Rameela Chandrasekhar; William O Cooper Journal: Ann Epidemiol Date: 2013-08 Impact factor: 3.797
Authors: Rachel M Hayes; Pingsheng Wu; Richard C Shelton; William O Cooper; William D Dupont; Ed Mitchel; Tina V Hartert Journal: Am J Obstet Gynecol Date: 2012-04-30 Impact factor: 8.661
Authors: Susan E Maloney; Shyam Akula; Michael A Rieger; Katherine B McCullough; Krystal Chandler; Adrian M Corbett; Audrey E McGowin; Joseph D Dougherty Journal: eNeuro Date: 2018-07-09